MARKET

ITRM

ITRM

Iterum Therapeutics plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6587
-0.0163
-2.41%
After Hours: 0.6300 -0.0287 -4.36% 19:58 09/18 EDT
OPEN
0.6800
PREV CLOSE
0.6750
HIGH
0.6800
LOW
0.6300
VOLUME
139.53K
TURNOVER
--
52 WEEK HIGH
7.19
52 WEEK LOW
0.5051
MARKET CAP
13.99M
P/E (TTM)
-0.1171
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average ITRM stock price target is 1.500 with a high estimate of 2.000 and a low estimate of 1.000.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ITRM
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The Company is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The Company is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. It is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. It has demonstrated potent in vitro activity against all genera of Enterobacteriacease, in anaerobes such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms including methicillin-susceptible staphylococci, Streptococcus pyogenes and Streptococcus pneumonia.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Iterum Therapeutics PLC stock information, including NASDAQ:ITRM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITRM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ITRM stock methods without spending real money on the virtual paper trading platform.